Enochian Biosciences

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

We believe that every person has the potential to contribute to a richer, healthier, and more sustainable world; it is our mission to make that world a reality for all. We strive to create innovative therapies that will improve the lives of those suffering from cystic fibrosis and other diseases.

Our vision is to be at the forefront of the biotechnology industry by discovering and developing innovative medicines that make a meaningful difference in the lives of cystic fibrosis patients, and to be a leader in the fields of genetics, precision medicine, and drug development.

Enochian Biosciences has several awards related to its innovation and patient-focused mission, including the 2020 San Francisco Business Times 2019 Health Care & Life Sciences Innovation Award, the 2019 Golden Catapult Award, and the 2018 Red Herring Top 100 North America Award.